Perineural Incobotulinumtoxin-A 200 U

PreclinicalSmall molecule

Perineural Incobotulinumtoxin-A 200 U is one of 9 small molecule programs targeting Complex Regional Pain Syndrome. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Complex Regional Pain SyndromeActive, not recruiting

Complex Regional Pain SyndromePreclinical

Active, not recruiting

Competition

Competitive Landscape

9 competitors in Complex Regional Pain Syndrome

#DrugCompanyPhaseTrials

Suboxone

IIndivior Inc.

Approved

1 2

Lyrica

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

1 3

Ketalar

AAultman Health Foundation

Approved

1 4

Aspercreme Warming

AAveritas Pharma, Inc.

Approved

—5

Neurontin

VViatris Specialty LLC

Preclinical

1 6

Botox

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

—7

Botox

RRevance Therapeutics, Inc.

Preclinical

—8

BRC-002

UUniversity of Colorado, Denver

Phase 1

1 9

Perineural Incobotulinumtoxin-A 200 U

BBo Biering-Soerensen

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Complex Regional Pain Syndrome1 trial

Perineural Incobotulinumtoxin-A for Complex Regional Pain Syndrome - An Open-label Feasibility Study

Recruiting·BBo Biering-Soerensen·N/A·NCT07473635·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Perineural Incobotulinumtoxin-A 200 U. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Perineural Incobotulinumtoxin-A 200 U compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Perineural Incobotulinumtoxin-A 200 U. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bo Biering-Soerensen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: BBo Biering-Soerensen

Perineural Incobotulinumtoxin-A 200 U

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Complex Regional Pain Syndrome1 trial

References

Drug Info

Quick Facts

Related News